In a nutshell The report recommends how to manage patients with chronic-phase chronic myeloid leukemia (CP-CML) who failed to respond to 2nd generation tyrosine kinase inhibitors (TKIs). The authors suggested to consider patient-specific factors and personalize treatment for such patients. Some background TKIs deactivate cancerous enzymes which cause...
Read More
In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia. This study concluded that high-dose treatment may be more effective in these patients in the long term. Some background Chimeric antigen...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of clofarabine, cytarabine, and mitoxantrone (CLAM) in relapsed or refractory (unresponsive) acute myeloid leukemia. This study concluded that this combination was safe and effective in these patients. Some...
Read MoreIn a nutshell The study evaluated the safety and effectiveness of blinatumomab (Blincyto) in patients with relapsed or unresponsive B-acute lymphoblastic leukemia (B-ALL) outside of clinical trials. The authors found that blinatumomab was safe and effective to treat such patients in real-world medical practice. Some background Relapsed...
Read MoreIn a nutshell This study aimed to investigate if ibrutinib was safe and effective as a salvage treatment after stem cell transplant in patients with chronic lymphocytic leukemia. This study concluded that ibrutinib is safe and effective as a salvage treatment in these patients. Some background Allogeneic...
Read More
In a nutshell This study aimed to investigate ponatinib combined with conventional therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with a BCR-ABL T315I mutation after allogeneic hematopoietic stem cell transplant. This study concluded that ponatinib may be effective for these...
Read More
In a nutshell This trial is evaluating the effectiveness of KRT-232 for the treatment of acute myeloid leukemia (AML). The main outcomes are the number of patients who achieve complete remission, and how many patients stop treatment due to side effects. This study is being conducted in Columbus, Ohio, United States. The details AML is a...
Read More
In a nutshell This study aimed to evaluate the relationship between minimal residual disease response and outcomes in patients with relapsed/unresponsive B-cell precursor acute lymphoblastic leukemia who were treated with blinatumomab. This study concluded that achieving minimal residual disease response leads to better outcomes for...
Read MoreIn a nutshell This trial is examining the effectiveness of modified stem cell transplants (SCT) donated by patient relatives, which have certain immune cells removed to prevent transplant rejection in patients with leukemia and lymphoma. The main outcome will be the maximum dose of SCT that can be given safely and is effective. This study is recruiting...
Read More
In a nutshell This study evaluated the safety and effectiveness of the herpes zoster vaccine (Shingrix) in patients with blood cancer who are receiving anti-cancer therapy. This study concluded that the Shingrix vaccine was effective in these patients, with manageable side effects. Some background Shingles is caused by a virus called herpes zoster....
Read MoreIn a nutshell This study analyzed the outcomes of allogeneic stem cell transplantation (alloSCT) in patients with acute myeloid leukemia (AML) who had experienced multiple relapses. The main finding was that those who received alloSCT while in complete remission for at least the third time had the best survival. Some background Complete...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of dasatinib as a second- and third-line therapy in patients with chronic phase chronic myeloid leukemia (CP-CML). This study concluded that dasatinib was effective as a second-line treatment in these patients but showed limited effectiveness as a third-line treatment....
Read More
